euro-biotechnology-genomics-congress-2018-tracks

13 / 19

Page 34
N o v e m b e r 2 6 - 2 7 , 2 0 1 8 | M a d r i d , S p a i n
&
&
BIOTECHNOLOGY
Euro Congress on
GENOMICS AND MOLECULAR BIOLOGY
International Conference on
CANCER SCIENCE AND THERAPY
Global Congress on
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Euro Biotechnology 2018 & Genomics Congress 2018 & Cancer Congress 2018 Journal of RNA and Genomics | ISSN: 2591-7781 | Volume 14
Joel I Osorio, J RNA Genomics 2018, Volume 14
REGENERAGE SYSTEM: THERAPEUTIC
EFFECTS OF COMBINATORIAL BIOLOGICS
(MRNA AND ALLOGENIC MSCS) WITH A
SPINAL CORD STIMULATION SYSTEM ON A
PATIENT WITH SPINAL CORD SECTION
Joel I Osorio
RegenerAge Clinic, Mexico
As it has been previously demonstrated that co-electroporation of Xenopus
laevis frog oocytes with normal cells and cancerous cell lines induces the
expression of pluripotency markers and in experimental murine model stud-
ies that mRNA extract (Bioquantine® purified from intra and extra oocyte liq-
uid phases of electroporated oocytes) showed potential as a treatment for a
wide range of conditions as squint, spinal cord injury (SCI) and cerebral palsy
among others. The current study observed beneficial changes with Bioquan-
tine® administration in a patient with a severe SCI. Pluripotent stem cells
have therapeutic and regenerative potential in clinical situations CNS disor-
ders even cancer. One method of reprogramming somatic cells into pluripo-
tent stem cells is to expose them to extracts prepared from Xenopus laevis
oocytes. We showed previously that co-electroporation of Xenopus laevis frog
oocytes; with normal cells and cancerous cells lines induces expression of
markers of pluripotency. We also observed therapeutic effects of treatment
with a purified extract (Bioquantine) of intra and extra oocyte liquid phases
derived from electroporated X. laevis oocytes on experimentally induced pa-
thologies including murine models of melanoma, traumatic brain injury and
experimental skin wrinkling induced by squalene-monohydroperoxide (Pay-
lian et. al, 2016). The positive human findings for spinal cord injury and ce-
rebral palsy with the results from previous animal studies with experimental
models of traumatic brain injury, respectively (Paylian et. al, 2016). Because
of ethical reasons, legal restrictions and a limited numbers of patients, we
were able to treat only a very small number of patients. These results indi-
cate that Bioquantine® may be safe and well tolerated for use in humans and
deserves further study in a range of degenerative disorders. We propose that
the mechanism of action of Bioquantine® in these various diseases derives
from its unique pharmacology and combinatorial reprogramming properties.
In conclusion, these preliminary findings suggest that Bioquantine is safe and
well tolerated on patients with cerebral palsy and spinal cord injury among
others. In addition to the regenerative therapy and due to the patient condi-
tion, we decided to include the restore-sensor sure scan. Based on the elec-
trical stimulation for rehabilitation and regeneration after spinal cord injury
published by Hamid and MacEwan, we designed an improved delivery method
for the in situ application of MSCs and Bioquantine® in combination with the
RestoreSensor® SureScan®.
Joel I Osorio is a innovative businessman with a distinct
entrepreneurial mindset concentrated in adding value
on the areas of Biotechnology (mRNA), Reprogram-
ming & Regenerative Medicine for translational use in
humans and a variety of clinical applications aimed for
both the private and the public health sectors. He is the
CEO of RegenerAge Clinic and RegenerAge Beauty. VP
and Clinical Developer for Bioquark, Inc., CCO at Rean-
ima Advance Biosciences Project. President at Jois an
anti-aging, beauty, and cosmetic products endorsement
company. VP and Chairman of the WAMS Americas Di-
vision. Earned MD degree at Westhill University. Diplo-
mate in aesthetic medicine (UAG), Advance Fellow by the
ABAARM, visiting scholar at UNC at Chapel Hill in Derma-
tology. Fellow in Stem Cell Medicine by the A4M and USF,
Business Diplomate at ECA, enrolled Master on Health
Sciences at Victoria University.
BIOGRAPHY
Conclusions: To the present day the patient who
suffered a total section of spinal cord at T12-L1
shows an improvement in sensitivity, strength in
striated muscle and smooth muscle connection,
11 months after the first therapy of cell regen-
eration and three month after the placement
of Restore Sensor® at the level of the lesion,
the patient with a complete medullary section
shows an evident improvement on his therapy of
physical rehabilitation on crawling from front to
back by himself and standing on his feet for the
first time and showing a progressively important
functionality on the gluteal and legs sensitivity.